Disclosure under Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (''SEBI Listing Regulations'') ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amwill Health Care's Board approved its H1 FY26 (April-September 2025) unaudited results on November 4, 2025. Revenue from operations fell to Rs. 2,120.50 lakhs from Rs. 2,315.60 lakhs in H1 FY25, an 8.4% decline. Total expenses jumped to Rs. 1,733.90 lakhs from Rs. 1,449.89 lakhs, pushing profit before tax down 40% to Rs. 526.40 lakhs. Profit after tax nearly halved to Rs. 387.40 lakhs (vs Rs. 651.66 lakhs), with EPS dropping to Rs. 1.94 from Rs. 4.18. Operating cash flow also weakened sharply to Rs. 263.74 lakhs from Rs. 1,014.63 lakhs a year ago. The company, which listed on the BSE SME platform in February 2025, still has Rs. 1,599.91 lakhs of IPO proceeds unutilized. Statutory auditors SKLR & Co. LLP issued a clean limited review report with no qualifications.
Despite revenue holding up reasonably, sharply higher expenses led to a steep drop in profits and operating cash flow, which is likely to weigh negatively on the stock. Investors should watch for margin recovery in H2 and updates on deployment of the remaining IPO funds.